CXCL9 and gastric adenocarcinoma: Expression of CXCL9/10/11/17 mRNA may be a promising prognostic indicator for Epstein-Barr virus associated STAD patients.[16] Another study revealed that CXCL9 was positively correlated with a better prognosis for STAD patients.[17] Moreover, combinations of initial serum ENA78/CXCL5 and SDF-1/CXCL12 can serve as serum biomarker panels to predict the presence and distant metastasis of STAD.[18] Qi et al suggested CXCL8 as a potential biomarker for predicting disease progression in STAD.[19]